{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T02:08:08Z","timestamp":1784945288954,"version":"3.55.0"},"reference-count":39,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T00:00:00Z","timestamp":1680739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Oritavancin is a long-acting lipoglycopeptide with in vitro activity against Gram-positive pathogens, as well as good bactericidal activity and sterilisation ability in biofilm. It has been approved for acute bacterial skin and skin structure infections (ABSSSI), but recent reports have demonstrated possible off-label uses, such as for vancomycin resistant enterococci (VRE), deep-seated infections including those involving prosthetic material and invasive infections. The aim of this work is to review the uses of oritavancin outside of ABSSSI, focusing on its real-life applications on infective endocarditis, catheter- or device-related infections, bloodstream infections, and bone and prosthetic joint infections in humans, as well as possible future applications. We performed a narrative review, collecting the literature published between 1 December 2002 and 1 November 2022 on PubMed and the Cochrane Library using the term \u2018oritavancin\u2019. Available studies have shown how effective it is in different settings, suggesting an opportunity for step-down strategies or outpatient management of infections requiring a long duration of antibiotic treatment. So far, evidence is still scarce, and limited to a few studies and case reports, mostly focusing on Staphylococcus aureus as the major isolate. Concerns about fluid intake for dilution and interaction with coagulation markers also need to be taken into account. Further studies are required in order to assess the safety and effectiveness of Oritavancin in vascular, prosthetic, or device-related infections, as well as in resistant Gram-positive bacteria or enterococcal infections.<\/jats:p>","DOI":"10.3390\/life13040959","type":"journal-article","created":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T03:59:55Z","timestamp":1680753595000},"page":"959","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Role of Oritavancin in the Treatment of Infective Endocarditis, Catheter- or Device-Related Infections, Bloodstream Infections, and Bone and Prosthetic Joint Infections in Humans: Narrative Review and Possible Developments"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3865-9519","authenticated-orcid":false,"given":"Tommaso","family":"Lupia","sequence":"first","affiliation":[{"name":"Unit of Infectious Diseases, Cardinal Massaia, 14100 Asti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"De Benedetto","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Infectious Diseases, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Bosio","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Infectious Diseases, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0171-9274","authenticated-orcid":false,"given":"Nour","family":"Shbaklo","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Infectious Diseases, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8338-0130","authenticated-orcid":false,"given":"Francesco Giuseppe","family":"De Rosa","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Cardinal Massaia, 14100 Asti, Italy"},{"name":"Department of Medical Sciences, Infectious Diseases, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Corcione","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Infectious Diseases, University of Turin, 10126 Turin, Italy"},{"name":"School of Medicine, Tufts University, Boston, MA 02111, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e0261420","DOI":"10.1128\/aac.02614-20","article-title":"New Perspectives on Antimicrobial Agents: Long-Acting Lipoglycopeptides","volume":"66","author":"Tran","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2146\/ajhp110572","article-title":"Oritavancin: An investigational lipoglycopeptide antibiotic","volume":"70","author":"Karaoui","year":"2013","journal-title":"Am. J. Health-Syst. Pharm. AJHP Off. J. Am. Soc. Health-Syst. Pharm."},{"key":"ref_3","unstructured":"(2022, November 05). Sintesi di Tenkasi e Perch\u00e9 \u00e8 Autorizzato Nell\u2019unione Europea (UE). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/tenkasi-previously-orbactiv-epar-summary-public_it.pdf."},{"key":"ref_4","unstructured":"(2022, November 05). Highlights of Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/206334s005lbl.pdf."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"ofac090","DOI":"10.1093\/ofid\/ofac090","article-title":"Kimyrsa, An Oritavancin-Containing Product: Clinical Study and Review of Properties","volume":"9","author":"Hoover","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Saddler, K., Zhang, J., Sul, J., Patel, P., Castro-Lainez, M., Stevens, M.L., Kosler, S., Lowery, E., and Sierra-Hoffman, M. (2021). Improved economic and clinical outcomes with oritavancin versus a comparator group for treatment of acute bacterial skin and skin structure infections in a community hospital. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0248129"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e01968-16","DOI":"10.1128\/AAC.01968-16","article-title":"Effects of Oritavancin on Coagulation Tests in the Clinical Laboratory","volume":"61","author":"Belley","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1056\/NEJMoa1310422","article-title":"SOLO I Investigators. Single-dose oritavancin in the treatment of acute bacterial skin infections","volume":"370","author":"Corey","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/cid\/ciu778","article-title":"SOLO II Investigators. Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: The SOLO II non-inferiority study","volume":"60","author":"Corey","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/QCO.0000000000000714","article-title":"Role or oritavancin and dalbavancin in acute bacterial skin and skin structure infections and other potential indications","volume":"34","author":"Bassetti","year":"2021","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s41073-019-0064-8","article-title":"SANRA-a scale for the quality assessment of narrative review articles","volume":"4","author":"Baethge","year":"2019","journal-title":"Res. Integr. Peer Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"ofv156","DOI":"10.1093\/ofid\/ofv156","article-title":"Prolonged Use of Oritavancin for Vancomycin-Resistant Enterococcus faecium Prosthetic Valve Endocarditis","volume":"2","author":"Johnson","year":"2015","journal-title":"Open Forum Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s40121-017-0156-z","article-title":"Real-World Experience with Oritavancin Therapy in Invasive Gram-Positive Infections","volume":"6","author":"Stewart","year":"2017","journal-title":"Infect. Dis. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40801-020-00192-w","article-title":"Clinical Outcomes and Economic Impact of Oritavancin for Gram-Positive Infections: A Single Academic Medical Center Health System Experience","volume":"7","author":"Brownell","year":"2020","journal-title":"Drugs-Real World Outcomes"},{"key":"ref_15","unstructured":"Terrero Salcedo, D.A., El-Herte, R., and Granada, M. (2018). Oritavancin for the Treatment of Infective Endocarditis due to Gram-positive Organism. Ann. Case Rep., ACRT-202."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1093\/jac\/dkz162","article-title":"On- and off-label utilization of dalbavancin and oritavancin for Gram-positive infections","volume":"74","author":"Morrisette","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Ahiskali, A., and Rhodes, H. (2020). Oritavancin for the treatment of complicated gram-positive infection in persons who inject drugs. BMC Pharmacol. Toxicol., 21.","DOI":"10.1186\/s40360-020-00452-z"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/phar.2057","article-title":"Multiple-Dose Oritavancin Evaluation in a Retrospective Cohort of Patients with Complicated Infections","volume":"38","author":"Schulz","year":"2018","journal-title":"Pharmacotherapy"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1177\/0018578717746415","article-title":"Evaluation of Oritavancin Use at a Community Hospital","volume":"53","author":"Co","year":"2018","journal-title":"Hosp. Pharm."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"ofz479","DOI":"10.1093\/ofid\/ofz479","article-title":"The CHROME Study, a Real-world Experience of Single- and Multiple-Dose Oritavancin for Treatment of Gram-Positive Infections","volume":"6","author":"Redell","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s40801-020-00195-7","article-title":"Treatment of Acute Osteomyelitis with Once-Weekly Oritavancin: A Two-Year, Multicenter, Retrospective Study","volume":"7","author":"Chundi","year":"2020","journal-title":"Drugs Real World Outcomes"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1002\/phar.1957","article-title":"Successful treatment of methicillin susceptible Staphylococcus aureus osteomyelitis with oritavancin","volume":"37","author":"Delaportas","year":"2017","journal-title":"Pharmacotherapy"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ijantimicag.2018.11.023","article-title":"Treatment of chronic osteomyelitis with multidose oritavancin: A case series and literature review","volume":"53","author":"Chastain","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e00949","DOI":"10.1016\/j.idcr.2020.e00949","article-title":"Successful treatment of a prosthetic hip infection due to Enterococcus faecalis with sequential dosing of oritavancin and prosthesis preservation without prosthetic joint surgical manipulation","volume":"22","author":"Nguyen","year":"2020","journal-title":"IDCases"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e02622-18","DOI":"10.1128\/AAC.02622-18","article-title":"Treatment of Multidrug-Resistant Vancomycin-Resistant Enterococcus faecium Hardware-Associated Vertebral Osteomyelitis with Oritavancin plus Ampicillin","volume":"63","author":"Dahesh","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_26","unstructured":"(2022, November 05). Oritavancin for Staphylococcus Aureus Infections in Opioid Users, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03761953."},{"key":"ref_27","first-page":"502","article-title":"Continued Dosing of Oritavancin for Complicated Gram-Positive Infections","volume":"37","author":"Meyer","year":"2020","journal-title":"Fed. Pract."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s40801-020-00188-6","article-title":"A Two-Dose Oritavancin Regimen Using Pharmacokinetic Estimation Analysis","volume":"7","author":"Rose","year":"2020","journal-title":"Drugs-Real World Outcomes"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"ofac492.698","DOI":"10.1093\/ofid\/ofac492.698","article-title":"Activity of Oritavancin and Comparator Agents Against Coagulase-negative Staphylococci Causing Bloodstream Infections in US Medical Centers (2017\u20132019)","volume":"9","author":"Carvalhaes","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1128\/AAC.50.3.994-1000.2006","article-title":"Pharmacokinetic-pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremia","volume":"50","author":"Bhavnani","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1128\/AAC.00766-08","article-title":"Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro","volume":"53","author":"Belley","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.diagmicrobio.2018.05.010","article-title":"In vitro activity of oritavancin against biofilms of staphylococci isolated from prosthetic joint infection","volume":"92","author":"Yan","year":"2018","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_33","first-page":"251","article-title":"Antistaphylococcal activity of oritavancin and its synergistic effect in combination with other antimicrobial agents","volume":"586","author":"Lin","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1128\/AAC.03006-15","article-title":"Oritavancin combinations with beta-lactams against multidrug-resistant Staphylococcus aureus and vancomycin-resistant enterococci","volume":"60","author":"Smith","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e00943-18","DOI":"10.1128\/AAC.00943-18","article-title":"Evaluation of Oritavancin Combinations with Rifampin, Gentamicin, or Linezolid against Prosthetic Joint Infection-Associated Methicillin-Resistant Staphylococcus aureus Biofilms by Time-Kill Assays","volume":"62","author":"Yan","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.diagmicrobio.2018.03.008","article-title":"In vitro activity of oritavancin against planktonic and biofilm states of vancomycin-susceptible and vancomycin-resistant enterococci","volume":"91","author":"Yan","year":"2018","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Lagatolla, C., Mehat, J.W., La Ragione, R.M., Luzzati, R., and Di Bella, S. (2022). In Vitro and In Vivo Studies of Oritavancin and Fosfomycin Synergism against Vancomycin-Resistant Enterococcus faecium. Antibiotics, 11.","DOI":"10.3390\/antibiotics11101334"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2174\/1871526517666161108130148","article-title":"Use of Oritavancin (Novel New Lipoglycopeptide) in the Treatment of Prosthetic Joint Infections (PJI): A Possible Alternative Novel Approach to a Difficult Problem","volume":"17","author":"Antony","year":"2017","journal-title":"Infect. Disord. Drug Targets"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/ofid\/ofx163.903","article-title":"Analysis of Oritavancin Activity Against Gram-Positive Clinical Isolates Responsible for Bacterial Endocarditis in United States and European Hospitals (2008\u20132016)","volume":"4","author":"Pfaller","year":"2017","journal-title":"Open Forum Infect. Dis."}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/13\/4\/959\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:10:55Z","timestamp":1760123455000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/13\/4\/959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,6]]},"references-count":39,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["life13040959"],"URL":"https:\/\/doi.org\/10.3390\/life13040959","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,6]]}}}